Paradigme (LYMRIT-37-01)

Name No. For Patients with Purpose
Paradigme (LYMRIT-37-01) 18-15

Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment.

To investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects.

CheckMate 744

Name No. For Patients with Purpose
CheckMate 744 17-07

Children, adolescents, and young adults with Classic Hodgkin Lymphoma whose disease has come back or did not respond to initial treatment.

The purpose of this study is to determine whether certain drug combinations are safe and effective.